FDA grants accelerated approval to Nuvalent lung cancer drug

Advertisement

The FDA granted accelerated approval to Nuvalent’s Nelkarmi (neladalkib) Nov. 17 for adults with previously treated, locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

The kinase inhibitor is approved for patients who previously received alectinib as their only ALK inhibitor, or at least two ALK inhibitors plus platinum-based chemotherapy, according to the FDA’s approval notice.

The approval was based on results from the phase 1/2 ALKOVE-1 trial, which evaluated the drug in two patient groups. Among 67 patients previously treated with alectinib, 49% responded to treatment, with 52% of responders maintaining their response for at least 12 months.

Among 155 patients who previously received multiple ALK inhibitors and platinum-based chemotherapy, the response rate was 32%, with 51% of responders maintaining their response for at least 12 months.

The drug’s prescribing information includes warnings for liver, kidney and eye toxicity, elevated creatine phosphokinase levels and embryo-fetal toxicity. The recommended dose is 150 mg orally once daily.

The FDA granted the application priority review. The drug also has breakthrough therapy and orphan drug designations.

Advertisement

Next Up in Pharmacy

Advertisement